Tuvirumab
Modify Date: 2024-01-11 18:21:26
Tuvirumab structure
|
Common Name | Tuvirumab | ||
|---|---|---|---|---|
| CAS Number | 138660-97-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TuvirumabTuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research[1][2]. |
| Name | Tuvirumab |
|---|
| Description | Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Tuvirumab (OST 577; SDZ-OST 577; 5 mg/kg; iv; single dose) followed by intravenous wild-type HBV, the MS-2 strain, directs against the a determinant of HBV surface antigen delayed but does not prevent experimental infection of HBV and hepatitis in the chimpanzee[1]. Tuvirumab (5 mg/kg; iv) has a half-life of 16.7 days in the chimpanzee[1]. |
| References |
| No Any Chemical & Physical Properties |